ANTIBODY AGAINST SARS-COV-2

The present invention provides a novel antibody having high binding affinity and infection neutralizing activity against classic SARS-CoV-2 (Wuhan strain) and also other variants, including the omicron strain. Provided is an antibody against SARS-CoV-2, the antibody being characterized by binding to a spike glycoprotein receptor binding domain (RBD) of SARS-CoV-2, and recognizing serine 443 or tyrosine 489 of the amino acid sequence of the spike glycoprotein..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 25. Jan. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

TAKAHASHI YOSHIMASA [VerfasserIn]
MORIYAMA SAYA [VerfasserIn]
YUMOTO KOUHEI [VerfasserIn]
KURODA DAISUKE [VerfasserIn]
ADACHI YU [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
C12P: Fermentation or enzyme-using processes to synthesis (...)
che
G01N: Investigating or analysing materials by determining (...)
tec

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08

Patentnummer:

WO2024019110

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA019160429